Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study

Neurology

Volumn 88, Issue 11, 2017, Pages 1062-1068

  Imtiaz, Bushra ^a   Tuppurainen, Marjo ^b,d   Rikkonen, Toni ^b,f   Kivipelto, Miia ^g   Soininen, Hilkka ^a,d   Kröger, Heikki ^b,e   Tolppanen, Anna Maija ^c  

^a Institute of Clinical Medicine Neurology   (United States)

^b Clinical Research Center   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Neurocenter ^*  (United States)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEMENTIA; DSM-IV; FEMALE; FOLLOW UP; HAZARD RATIO; HORMONAL THERAPY; HOSPITAL DISCHARGE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MIDDLE AGED; NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SOCIOECONOMICS; STROKE ALZHEIMER DISEASE AND RELATED DISORDER ASSOCIATION CRITERIA; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; ESTROGEN THERAPY; EXERCISE; FINLAND; REGISTER;

AGED; ALZHEIMER DISEASE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXERCISE; FEMALE; FINLAND; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTMENOPAUSE; REGISTRIES; SURVEYS AND QUESTIONNAIRES;

EID: 85015150383     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003696     Document Type: Article

References (37)

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016;12.
2. Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 2001;153:132-136.
3. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 1997;49:1498-1504.
4. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav 2013;63:301-307.
5. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161-1168.
6. Nilsson LV. Incidence of severe dementia in an urban sample followed from 70 to 79 years of age. Acta Psychiatr Scand 1984;70:478-486.
7. Brinton RD, Chen S, Montoya M, Hsieh D, Minaya J. The estrogen replacement therapy of the Women's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas 2000;34(suppl 2):S35-S52.
8. Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev 2010;31:224-253.
9. Tanapat P, Hastings NB, Reeves AJ, Gould E. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. J Neurosci 1999;19:5792-5801.
10. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002;3:433-442.
11. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
12. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer's Disease Cooperative Study. JAMA 2000;283: 1007-1015.
13. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061-2066.
14. Shumaker SA, Legault C, Rapp SR, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmeno-pausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289: 2651-2662.
15. Shao H, Breitner JC, Whitmer RA, et al; Cache County Investigators. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012;79:1846-1852.
16. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163-169.
17. Barnes LL, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777-1781.
18. Brenner DE, Kukull WA, Stergachis A, et al. Postmeno-pausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-267.
19. Roberts RO, Cha RH, Knopman DS, Petersen RC, Rocca WA. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings. Alzheimer Dis Assoc Disord 2006;20:141-146.
20. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol 2001;58:435-440.
21. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52:965-970.
22. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-261.
23. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-2217.
24. Solomon A, Ngandu T, Soininen H, Hallikainen MM, Kivipelto M, Laatikainen T. Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers. Alzheimers Dement 2014;10:303-309.
25. Suhonen J, Pirttila T, Erkinjuntti T, et al. Suomalaisen laakariseuran duodecimin, societas gerontologica Fenni-can, suomen neurologisen yhdistyksen, suomen psykoger-iatrisen yhdistyksen, suomen yleislaaketieteen yhdistyksen asettama tyoryhma, update on current care guidelines: the diagnosis and medical treatment of memory disorders. Duodecim 2010;126:2167-2168.
26. Quick Reference to the Diagnostic Criteria From DSM-IV-TR. Washington, DC:American Psychiatric Association; 2000.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
28. Sandini L, Pentti K, Tuppurainen M, Kroger H, Honkanen R. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008;15: 282-289.
29. Shumaker SA, Legault C, Kuller L, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
30. Pentti K, Tuppurainen MT, Honkanen R, et al. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 2009; 160:979-983.
31. Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S. Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 2006;154:101-107.
32. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C; PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-17.
33. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA; MIRAGE Study Group. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76: 103-105.
34. Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology 2009;73:1729-1737.
35. Ryan J, Carriere I, Scali J, Ritchie K, Ancelin ML. Lifetime estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology 2009;34:287-298.
36. Zandi PP, Carlson MC, Plassman BL, et al; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-2129.
37. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.